ABBV has rebounded after Humira patent cliff, with Skyrizi and Rinvoq driving growth. Rising estimates and a pipeline set to ...

Both Skyrizi and its cousin Rinvoq have landed in the annual top three, in varying positions, since 2022. That was once again the case in 2025, when Skyrizi retained its place at the top and Rinvoq ...

The first two days of the J.P. Morgan Healthcare Conference are in the books, and attendees are now pushing through to finish ...

AbbVie continues to project low single-digit growth through 2030 as it expands its immunology franchise and makes a major ...

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2026, according to Statista. The oncology segment alone is expected to generate $232 billion in sales this year.

AbbVie reached a deal with the Trump administration on drug prices in exchange for being exempted from tariffs and future ...

ABBV stock falls 3% in a month amid takeover rumor denials, but Skyrizi and Rinvoq momentum and a deep pipeline support ...

A phase 3 rheumatoid arthritis trial of Lynk Pharmaceuticals’ JAK1 inhibitor in China has hit its primary endpoint, boosting ...

AbbVie’s latest valuation update comes with only a marginal trim to its fair value estimate, shifting from about US$244.68 to ...

Insmed’s Brinsupri blew past consensus estimates in its first full quarter on the market. Elsewhere, J&J inked pharma’s ...

Vicks accrued a total of 4.3 billion impressions on an estimated national TV ad spend of $18.9 million. The top network for ...

AbbVie ABBV generates a substantial portion of its revenues from its immunology franchise, driven by the encouraging uptake ...